Cargando…

Clinical and Mechanistic Review of Amiodarone-Associated Optic Neuropathy

Amiodarone-associated optic neuropathy (AAON) is a complex clinical diagnosis, requiring distinction from non-arteritic ischemic optic neuropathy (NAION) due to a shared at-risk patient population. Diagnosis of AAON is complicated by a varied clinical presentation and incomplete pathophysiologic mec...

Descripción completa

Detalles Bibliográficos
Autores principales: Mitchell, Reece, Chacko, Joseph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9496374/
https://www.ncbi.nlm.nih.gov/pubmed/36139137
http://dx.doi.org/10.3390/biom12091298
_version_ 1784794253310820352
author Mitchell, Reece
Chacko, Joseph
author_facet Mitchell, Reece
Chacko, Joseph
author_sort Mitchell, Reece
collection PubMed
description Amiodarone-associated optic neuropathy (AAON) is a complex clinical diagnosis, requiring distinction from non-arteritic ischemic optic neuropathy (NAION) due to a shared at-risk patient population. Diagnosis of AAON is complicated by a varied clinical presentation and incomplete pathophysiologic mechanisms. This article reviews pertinent literature for describing and clinically delineating AAON from NAION, as well as newly reported protective mechanisms of insulin-like growth factor 1 (IGF-1) and PI3K/Akt against amiodarone-induced oxidative and apoptotic injury in retinal ganglion and pigment epithelial cells. These studies offer a basis for exploring mechanisms of amiodarone toxicity in the optic nerve.
format Online
Article
Text
id pubmed-9496374
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-94963742022-09-23 Clinical and Mechanistic Review of Amiodarone-Associated Optic Neuropathy Mitchell, Reece Chacko, Joseph Biomolecules Review Amiodarone-associated optic neuropathy (AAON) is a complex clinical diagnosis, requiring distinction from non-arteritic ischemic optic neuropathy (NAION) due to a shared at-risk patient population. Diagnosis of AAON is complicated by a varied clinical presentation and incomplete pathophysiologic mechanisms. This article reviews pertinent literature for describing and clinically delineating AAON from NAION, as well as newly reported protective mechanisms of insulin-like growth factor 1 (IGF-1) and PI3K/Akt against amiodarone-induced oxidative and apoptotic injury in retinal ganglion and pigment epithelial cells. These studies offer a basis for exploring mechanisms of amiodarone toxicity in the optic nerve. MDPI 2022-09-14 /pmc/articles/PMC9496374/ /pubmed/36139137 http://dx.doi.org/10.3390/biom12091298 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Mitchell, Reece
Chacko, Joseph
Clinical and Mechanistic Review of Amiodarone-Associated Optic Neuropathy
title Clinical and Mechanistic Review of Amiodarone-Associated Optic Neuropathy
title_full Clinical and Mechanistic Review of Amiodarone-Associated Optic Neuropathy
title_fullStr Clinical and Mechanistic Review of Amiodarone-Associated Optic Neuropathy
title_full_unstemmed Clinical and Mechanistic Review of Amiodarone-Associated Optic Neuropathy
title_short Clinical and Mechanistic Review of Amiodarone-Associated Optic Neuropathy
title_sort clinical and mechanistic review of amiodarone-associated optic neuropathy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9496374/
https://www.ncbi.nlm.nih.gov/pubmed/36139137
http://dx.doi.org/10.3390/biom12091298
work_keys_str_mv AT mitchellreece clinicalandmechanisticreviewofamiodaroneassociatedopticneuropathy
AT chackojoseph clinicalandmechanisticreviewofamiodaroneassociatedopticneuropathy